UY36190A - Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación - Google Patents

Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación

Info

Publication number
UY36190A
UY36190A UY0001036190A UY36190A UY36190A UY 36190 A UY36190 A UY 36190A UY 0001036190 A UY0001036190 A UY 0001036190A UY 36190 A UY36190 A UY 36190A UY 36190 A UY36190 A UY 36190A
Authority
UY
Uruguay
Prior art keywords
rosuvastatin
oral administration
ezetimiba
preparation
composite formulation
Prior art date
Application number
UY0001036190A
Other languages
English (en)
Spanish (es)
Inventor
Seung Jun Lee
Ha Young Jeong
Kyeong Soo Kim
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54938391&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36190(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY36190A publication Critical patent/UY36190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY0001036190A 2014-06-25 2015-06-24 Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación UY36190A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020140078388A KR101977785B1 (ko) 2014-06-25 2014-06-25 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법

Publications (1)

Publication Number Publication Date
UY36190A true UY36190A (es) 2015-10-30

Family

ID=54938391

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036190A UY36190A (es) 2014-06-25 2015-06-24 Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación

Country Status (10)

Country Link
KR (1) KR101977785B1 (ko)
AR (1) AR100977A1 (ko)
BR (1) BR112016030111A2 (ko)
CL (1) CL2016003283A1 (ko)
EC (1) ECSP16096477A (ko)
JO (1) JOP20150154B1 (ko)
SG (2) SG11201610748RA (ko)
TW (1) TWI700100B (ko)
UY (1) UY36190A (ko)
WO (1) WO2015199356A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ2016539A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy
CZ2016538A3 (cs) 2016-09-05 2018-03-14 Zentiva, K.S. Farmaceutická kompozice obsahující dvě rozdílné účinné látky
KR102206535B1 (ko) * 2016-11-29 2021-01-22 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
EP3437636A1 (en) * 2017-08-02 2019-02-06 Adamed sp. z o.o. Pharmaceutical composition comprising ezetimibe
KR102500643B1 (ko) * 2019-04-18 2023-02-16 한미약품 주식회사 에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
KR20200137243A (ko) 2019-05-29 2020-12-09 콜마파마(주) 로수바스타틴 및 에제티미브를 포함하는 복합제의 제조방법
WO2021019499A1 (en) 2019-07-31 2021-02-04 TECNIMEDE - Sociedade Técnico-medicinal, SA Solid oral multiple-unit immediate release compositions, methods and uses thereof
TW202224681A (zh) * 2020-08-25 2022-07-01 南韓商大熊製藥股份有限公司 用於治療或預防高血壓及高膽固醇血症之單一劑型的醫藥組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100907144B1 (ko) * 2007-09-05 2009-07-09 박재섭 이동부재를 이용한 골프 클럽
WO2009024889A2 (en) * 2007-08-21 2009-02-26 Ranbaxy Laboratories Limited Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe
EP2448919A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility and stability enchancing pharmaceutical formulation
EP2459175B1 (en) * 2009-07-28 2017-11-01 Egis Gyógyszergyár Zrt. New granulating process and thus prepared granulate
EP2468258A1 (en) * 2010-12-22 2012-06-27 LEK Pharmaceuticals d.d. Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient
EP2844233B1 (en) * 2012-05-01 2020-05-06 Althera Life Sciences, LLC Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases

Also Published As

Publication number Publication date
ECSP16096477A (es) 2017-01-31
TW201625223A (zh) 2016-07-16
BR112016030111A2 (pt) 2017-08-22
KR20160000762A (ko) 2016-01-05
KR101977785B1 (ko) 2019-05-14
JOP20150154B1 (ar) 2021-08-17
SG11201610748RA (en) 2017-01-27
CL2016003283A1 (es) 2017-07-28
TWI700100B (zh) 2020-08-01
WO2015199356A1 (en) 2015-12-30
SG10201811586YA (en) 2019-02-27
AR100977A1 (es) 2016-11-16

Similar Documents

Publication Publication Date Title
UY36190A (es) Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2016002517A1 (es) Uso de ácido r-2-4-2-etoxi-3-4-trifluormetilfenoxipropil-tio-2-metilfenoxi acético o una sal del mismo en la fabricación de un medicamento para tratar una condición que es una enfermedad de hígado graso no alcohólico o esteatohepatitis no alcohólica.
CL2016001895A1 (es) Compuestos
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20180253A (es) Composiciones terapéuticas para el tratamiento del virus de unmunodeficiencia humana
DOP2014000255A (es) Uracilos sustituidos bicíclicamente y uso de los mismos
AR103077A1 (es) Método para la producción de un sistema de administración farmacéutica
EA201791259A1 (ru) Производные пиперидина в качестве ингибиторов hdac1/2
NZ731118A (en) Dopamine d3 receptor antagonists compounds
GT201700058A (es) Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos
CL2015003468A1 (es) Composicion solida para administracion oral conteniendo acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
BR112017008993A2 (pt) métodos e composições especificamente para o tratamento de transtorno de déficit de atenção
PH12017502260A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
PH12015500823A1 (en) Modified release formulations for oprozomib
DOP2016000297A (es) Composiciones farmacéuticas útiles para tratar enfermedades infecciosas
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов
UY36123A (es) Derivados de carboxamida
UY36124A (es) Derivados de carboxamida
AR099943A1 (es) Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso
DK3258920T3 (da) Fast farmaceutisk doseringsform, der er egnet til anvendelse som drikkevandsmedikament
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
TR201908937T4 (tr) P38 MAP kinazı inhibe eden indanil üre bileşikleri.
ECSP17008187A (es) Formas de dosificación farmacéutica

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705